That in turn drives up premiums, pressing away younger, healthier people who are vital to a working insurance system’ . This content can be republished with kind authorization from our friends at The Kaiser Family Foundation. You can view the complete Kaiser Daily Health Policy Statement, search the archives, or sign up for email delivery of in-depth coverage of wellness policy developments, discussions and debates. The Daily Health Policy Report is released for Kaisernetwork.org, a free of charge service of The Henry J.Based on the findings, only 1 1.4 % of the 70 early-stage breast cancer individuals treated with this regimen experienced congestive heart failure after 28 months of follow-up. This price of cardiac toxicity is leaner compared to the 4 % threshold that is generally considered acceptable, and lower than what was found in larger still, previously published trials analyzing conventionally scheduled treatment by using trastuzumab. The study’s authors figured this dose-dense regimen combined with trastuzumab is normally a safe and effective way to treat women with early-stage HER2-positive breast tumor in the adjuvant placing and there is no need to forgo the use of this regimen because trastuzumab is also being administered..